Patent intelligence · US
US 11484523
Compositions for prevention and treatment of symptoms associated with alcohol consumption
Compositions for prevention and treatment of symptoms associated with alcohol consumption
Patent details — US 11484523
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 1, 2022
- Expiration
- Oct 27, 2042
- Applicant
- Purple Biosciences LLC
- Claims
- 20
- CPC classes
- A61K, A61K31/198, A61K31/351, A61K31/352
Quick answer
US 11484523 (Compositions for prevention and treatment of symptoms associated with alcohol consumption) is held by Purple Biosciences LLC. Status: granted. Granted Nov 1, 2022. Expires Oct 27, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Purple Biosciences LLC
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/198, A61K31/351, A61K31/352, A61K31/366, A61K31/7034
More from Purple Biosciences LLC
Related pharmaceutical patents in our USPTO index.
Related coverage
Frequently asked questions
What is US patent 11484523?
US 11484523 (Compositions for prevention and treatment of symptoms associated with alcohol consumption) is held by Purple Biosciences LLC. Status: granted. Granted Nov 1, 2022. Expires Oct 27, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11484523?
Purple Biosciences LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 11484523 expire?
Our index shows an expiration date of Oct 27, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.